Antisense-oligonucleotide - Ein universelles therapieprinzip

Chemie in Unserer Zeit

Volumn 32, Issue 3, 1998, Pages 150-160

  Uhlmann, Eugen ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0032381008     PISSN: 00092851     EISSN: None     Source Type: Journal    
DOI: 10.1002/ciuz.19980320306     Document Type: Article

References (18)

1. "Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide": P. C. Zamecnik und M. L. Stephenson, Proc. Natl. Acad. Sci. USA 1978, 75, 280-284.
2. "Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide": M. L. Stephenson und P. C. Zamecnik, Proc. Natl. Acad. Sci. USA 1978, 75, 285-288.
3. "Antisense oligonucleotides: A new therapeutic principle": E. Uhlmann und A. Peyman, Chem. Rev. 1990, 90, 543-584.
4. "Oligonucleotide analogs containing dephosphointernucleoside linkages": E. Uhlmann und A. Peyman, in Methods Mol. Biol. Vol. 20 (Hrsg.: S. Agrawal), Humana Press, Totowa, N. J., 1993, S. 355-389.
5. "Antisense: Chemical Modifications": E. Uhlmann, A. Peyman und D. W. Will, in Encyclopedia of Cancer Vol. 1 (Hrsg.: S. Bertino), Academic Press, San Diego, 1997, S. 64-81.
6. "Antisense Research and Applications": (Hrsg.: S. T. Crooke und B. Lebleu), CRC Press, Boca Raton, FL, 1993.
7. "PNA: Synthetische Polyamid-Nucleinsäuremimetica mit außergewöhnlichen Bindungseigenschaften": F. Uhlmann, A. Peyman, G. Breipohl und D. W. Will, Angew. Chem., im Druck.
8. "Peptide nucleic acids (PNA): Synthesis, properties and potential applications": B. Hyrup und P. E. Nielsen, Bioorg. Med. Chem. 1996, 4, 5-23.
9. "The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes": S. Freier und K. H. Altmann, Nucleic Acids Res. 1997, 25, 4429-4443.
10. "Advances in understanding the pharmacological properties of antisense oligonucleotides": S. T. Crooke, Adv. Pharmacol. 1997, 40, 1-48.
11. "Antisense oligonucleotides: towards clinical trials": S. Agrawal, TIBTECH 1996, 14, 376-387.
12. "Isis Pharmaceuticals: What is the sense in antisense": S. M. Thomas und J. Burke, Exp. Opin. Ther. Patents 1997, 7, 813-819.
13. "In vivo studies with antisense oligonucleotides": S. Akhtar und S. Agrawal, Trends in Pharm. Sci. 1997, 18, 12-18.
14. "Advances in the synthesis of oligonucleotides by the phosphoramidite approach": S. Beaucage und R. Iyer, Tetrahedron 1992, 48, 2223-2311.
15. "Gene synthesis machines: DNA chemistry and its uses": M. H. Caruthers, Science 1985, 230, 281-285.
16. "Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides": N. M. Dean und R. McKay, Proc. Natl. Acad. Sci. USA 1994, 91, 11762-11766.
17. "Minimally modified oligonucleotides -combination of end-capping and pyrimidine-protection": A. Peyman und E. Uhlmann, Biol. Chem. Hoppe-Seyler 1996, 377, 67-70.
18. "c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption": S. Tanaka, M. Amling, L. Neff, A. Peyman, E. Uhlmann, J. B. Levy und R. Baron, Nature 1996, 383, 528-531.